Mumbai Teen Becomes World's Youngest Shoulder-Level Arm Transplant Recipient
18 October,2024 Read More 
Dr. (Brig) S. Viswanath 
Visiting Consultant
36 Years of ExperienceMedical Oncologist
MBBS, MD, DM
Reg. No.:153389, Tamil Nadu Medical Council
English, Hindi, Tamil
Consultation Fee ₹ 800
Book an AppointmentAbout Dr. (Brig) S. Viswanath
- Dr. (Brig) S. Viswanath is a well-known Medical Oncologist with over 36 years of experience.
- Dr. Viswanath brings extensive expertise to the field of medical oncology, specializing in gastrointestinal cancers, colorectal cancer, liquid tumors, and head and neck cancers.
- His clinical practice revolves around providing advanced treatments such as chemotherapy, immunotherapy, and targeted therapy aimed at delivering optimal outcomes for his patients.
- Dr. Viswanath's educational qualifications include an MBBS from Karnataka Medical College, Hubli, obtained in 1988, followed by an MD in General Medicine from Command Hospital, Airforce, Bangalore in 2000.
- He earned a DM in Medical Oncology from the Cancer Institute (WIA), Chennai, in 2006.
- He has enriched his career with international experience at renowned hospitals, contributing significantly to the global oncology community.
- Dr. Viswanath has received several prestigious awards and medals, including the Shigikara Award from AFLA (Asian Federation of Laryngectomees Association) in 2014.
- His academic contributions are notable, with publications in peer-reviewed journals like the Indian Journal of Rheumatology and the Journal of Cancer Metasta Treat.
- He is a reputable member of several organizations, including the Royal College of Surgeons Edinburgh, the Indian Surgical Oncology Society, and the City Surgical Oncologist Group.
Book Your Appointment With Dr. (Brig) S. Viswanath
Get a Treatment Plan Within 1 Hour
Education
- MBBS, Karnataka Medical College, Hubli, 1988
- MD in General Medicine, Command Hospital Air Force, Bangalore, 2000
- DM in Medical Oncology, Cancer Institute (WIA), Chennai, 2006
Past Experience
- Commandant, Military Hospital, Chennai, 2021
- Consultant, Medicine & Medical Oncology, Command Hospital (CC), Lucknow, 2020
- Professor, Senior Advisor, Medicine & Medical Oncology, Command Hospital (CC), Lucknow, 2020
- Professor, Senior Advisor, Medicine & Medical Oncology, Army Hospital (R&R), 2018
- Associate Professor, Senior Advisor, Medicine & Medical Oncology, Army Hospital (R&R), 2016
- Associate Professor, Senior Advisor, Medicine & Medical Oncology, Command Hospital (EC), 2012
- Assistant Professor, Classified Specialist in Medicine and Medical Oncology, Command Hospital (EC), 2011
- Assistant Professor, Classified Specialist in Medicine and Medical Oncology, Command Hospital (WC), 2009
Awards
- Shigikara Award, Asian Federation of Laryngectomees Association (AFLA), 2014
Associations/Membership
- Royal College of Surgeons Edinburgh
- Association of Surgeons of India
- Indian Surgical Oncology Society
- City Surgical Oncologist Group
Paper Published
- Singal V K, Viswanath S, Chengappa ANM. Two cases of refractory rheumatoid arthritis treated with Rituximab; Indian Journal of Rheumatology, Vol2, Issue 3,S27:sept 2007.
- Sundaram V,Sanyal N. Clinicopathological profile of bronchogenic carcinoma in a tertiary care hospital in eastern part of India. Clinical Cancer Investig J 2014;3:220-4.
- Darling HS, Viswanath S, Rajeev V. T- lymphoblastic lymphoma in an undiagnosed rheumatoid arthritis- A rare occurrence. Indian Journal of Rheumatology,Vol. 10, Issue 1,p48-50, 2015.
- Viswanath S, Pathak A, Kapoor A, Rathore A, Kapur BN. Changing paradigm in treatment of lung cancer. J Cancer Metasta Treat 2016;2:214-9.
- Sundaram V. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman’s disease) with systemic involvement. Afr J Med Health Sci 2016;15:62-4.
- Dubey AP, Viswanath S. A case of metastatic insulinoma: Management and review of literature. OGH Reports, 2016; 5(2):79-81.
- Viswanath S, Pathak A. Management of HER2-positive breast cancer: A review. J NTR Univ Health Sci 2016;5:87-92.
- Pathak A, Viswanath S, Rathore A, Dubey AP. Paraneoplastic limbic encephalitis forgotten etiology of altered sensorium. Int J Adv Med 2016;3:771-3.
- Dubey AP*, Viswanath S, Suhag V, Pathak A, Rathore A, Kapoor A. Oral voriconazole causing severe hypokalemia, acute quadriplegia and prolonged qt interval: a rare case report, wjpmr, 2016, 2(2).
- Kapoor A, Viswanath S, Ranjan S, Kapur BN. A Clinico demographic Study of Receptor status in Carcinoma Breast. J Carcinog 2016, 15:2(7 April 2016) (ACOS Abstracts):S162.
- Rajeev V, Kapur A, Viswanath S, Kapur BN. Primary CNS Lymphoma in Immunocompetent Patient – Case Series. J Carcinog 2016, 15:2(7 April 2016) (ACOS Abstracts):S215.
- Purkayasta A, Sharma N, Viswanath S, Sunitha B. Adenoid Cystic Carcinoma of Lung: A oncological rarity treated with definitive chemoradiation.Int JCancer Ther Oncol.2016; 4(3):4315
- Purkayastha A, Pathak A, Sharma N, Viswanath S, Dutta V. Primitive neuroectodermal tumor of lungs in adults: a rare series of three cases treated with upfront chemo-radiation. Transl Lung Cancer Res 2016;5(3):350-355.
- Pathi N, Viswanath S, Pathak A, Rathore A, Prukayasta A. Receptor tyrosine kinase signalling pathways: a review. Int J Adv Med.2016 Oct 26;3(4):783-9.
- Viswanath S, Bhardwaj R, kapoor A. Clinicopathological significance of epidermal growth factor receptor and vascular endothelial growth factor expression in biliary tract malignancies. J NTR Univ Health Sci 2017;6:82-5.
- Dubey AP, Vishwanath S, Nikhil P, Rathore A, Pathak A. Microsatellite instability in stage II colorectal cancer: An Indian perspective. Indian J Cancer 2016;53:513-7.
- Dubey AP,Singh R, Pathak A, Viswanath S, Rathore A, Pathi N. Clinical profile, prognostication and treatment outcomes in non Hodgkin’s lymphoma. Int J Adv Med 2017;4:1184-8.
- Singh R, Viswanath S, Maleskar D. Clinical profile and outcomes of granulocytic sarcoma among myeloid malignancies treated in a tertiary care center. Clin Cancer Investig J 2017;6:56-61.
- Carcinoma of the Unknown primary- Knowing the unknown facts. Pathak A, Gupta A, Rathore A, Vishwanath S. World J Pharm Sci2018; 6(1): 40-46.
- Dubey A P, Vishwanath S, Nikhil P, Rathore A, Pathak A, Kumar R. Microsatellite instability in stage II and III colorectal cancer: Patterns and profile. Indian J Med Paediatr Oncol [serial online] 2018 [cited 2018 Jan 29];39:36-41.
- Dubey A P, Pathi N, Rathore A, Viswanath S, Pathak A, Sud R, Rai S K. Clinicopathological profile of anaplastic lymphoma kinase-positive non small cell lung cancer: An Indian perspective. Indian J Med Paediatr Oncol [serial online] 2018 [cited 2018 Jan 29];39:32-5.
- Dubey AP, Rawat K, Pathi N, Viswanath S, Rathore A, Kapoor R, et al. Carcinoma of gall bladder: Demographic and clinicopathological profile in Indian patients. Oncol J India 2018;2:3-6.
- Purkayasta A, Sharma N, Viswanath S, Sunitha B. Adenoid Cystic Carcinoma of Lung: A oncological rarity treated with definitive chemoradiation..Int J Cancer Ther Oncol.2016; 4(3):4315
- Incidence of K-RAS mutation in metastatic colorectal carcinoma and further to find any associated correlation between K-RAS mutation and various demographic and clinical factors. A Hospital based study(#652) Altaf Ali 1 , A K Dhar 2 , Bhupender Kapur 2 , Dharmesh Soneji 2 , Amul Kapoor 2 , S Viswanath 2 E Poster 2014 WCC
- Sharma N, Purkayastha A, Vishwanath S, Jaiswal P. To compare and determine the diagnostic accuracy of [18F]- fluorodeoxyglucose positron emission tomography scan in predicting pathological response in operated carcinoma esophagus patients after initial neoadjuvant chemoradiation and neoadjuvant chemotherapy. World J Nucl Med2018;17:79-85.
- Dubey A P, Pathi N, Viswanath S, Rathore A, Pathak A, Sud R. New insights into anaplastic lymphoma kinase-positive non small cell lung cancer. Indian J Cancer 2017;54:203-8
- Rathore A, Ranjan S, Vishwanath S, Pathak A, Dubey A P, Nikhil P. BRCA 1 and 2 mutations in carcinoma breast: An Indian study. Clin Cancer Investig J 2018;7:97-103
- Darling HS, Viswanath S, Singh Randeep.Medication Related osteonecrosis of Jaw- A medical oncologist’s perspective.International Dental Journal of Student’s Research 2018;6(1):1-6
- A clinic- epidemiological, pathological and molecular study of lung cancer in Northwestern India. Darling HS, Viswanath S, Singh R, Ranjan S, Pathi N, Rathore A, Pathak A, Sud R. DOI: 10.4103/jcrt.JCRT_473_17
- Lohia, N., Prashar, M., Singh, S,Bhatnagar S, Viswanath S, Anand S, et al.Epidemiological and survival Trends in patients of Cancer of Uterine Cervix Treated with Definitive Concurrent Chemoradiotherapy: Obsevations from a North Indian Hospital Based Cancer Registry. Indian J Gynecol Oncology (2019) 17: 44
- Lohia N, Bhatnagar S, Singh S Prasher M, Subramaniam A, Viswanath S, et al. Survival trends in oral cavity cancer patients treated with surgery and adjuvant radiotherapy in a tertiary centre of Northern India. Where do we stand compared to the developed world? SRM J Res Dent Sci 2019,10 26-31.
- Prasher M, Soneji D, Viswanath S, Singh S. Cardiotoxicity with sequential use of Antharacycline and Transtuzumab in carcinoma breast patients in a North Indian tertiary care centre. J NTR Univ Health Sci 2019, 8: 83-8.
- Bisht N, Bhatnagar S, Viswanath S,Singh S, Lohia N. A comparative study of two protocols of concurrent chemotherapy with external beam radiotherapy in treatment of locally advanced cervical cancer: Cisplatin versus cisplatin plus capecitabine combination. Indian Journal of Gynecologic Oncology (2021)19:18
Field of Expertise
- Adrenal Cancer Treatment
- Bacillus Calmette Guerin (BCG) Therapy
- Benign and Cancerous Tumor Excision
- Bile Duct Cancer Treatment
- Bone Marrow Transplant
- Brain Tumor Surgery
Best Oncology Doctors in India
Dr. Ashok Kumar Vaid
Chairman
Medical Oncologist
Medanta - The Medicity Hospital, Gurgaon
Book an Appointment Talk To Expert
Dr. Satya Pal Kataria
Vice Chairman
Medical Oncologist
Medanta - The Medicity Hospital, Gurgaon
Book an Appointment Talk To Expert
Dr. Chandragouda Dodagoudar
Director
Medical Oncologist
BLK-Max Super Speciality Hospital, New Delhi
Book an Appointment Talk To Expert
Dr. Kunjahari Medhi
Senior Director
Medical Oncologist
Medanta - The Medicity Hospital, Gurgaon
Book an Appointment Talk To Expert